Table 1.

Pediatric cases of SJS/TEN treated with etanercept in the literature.

	Age	Sex	Culprit drug	BSA	Onset date (before admission)	Dose of etanercept	Date of administration	Other treatments	Inpatient days	6 months follow-up
This study	44 months	M	Deflazacort	60%	4 days before	0.8 mg/kg/dose	HD 6, 15	IV dexamethasone 1.5 mg/kg for 4 days IVIG 0.4 mg/kg/day for 5 days Cyclosporine 3 mg/kg/day	19	Postinflammatory hyperpigmentation, improving
1 (18)	2 years	M	Ibuprofen or acetaminophen	(–)*	(–)*	0.4 mg/kg/dose	HD 6, 8	Prednisone 1 mg/kg for 10 days IVIG 1 g/kg/d for 4 days	52	Persistent skin dyspigmentation
2 (19)	11 years	F	SMX/TMP	25%	(–)*	25 mg (0.75 mg/kg/dose)	HD 4, 5	IV methylprednisolone 30 mg/kg for 4 days Cyclosporine 5 mg/kg/day for 3 days	(–)*	(–)*
3 (20)	17 years	M	Carbamazepine	45%	(–)*	50 mg (0.8 mg/kg/dose)	HD 1	IV dexamethasone 1 mg/kg for 3 days Cyclosporine 3 mg/kg for 7 days 1.5 mg/kg for 7 days	14	No sequelae
4 (21)	4 years	M	SMX/TMP	12%	4 days before	0.8 mg/kg/dose or 50 mg	HD 1	none	17	Postinflammatory hyperpigmentation, mild atrophic scarring, dry eye disease
5 (21)	7 years	F	acetaminophen or influenza vaccine	50%	4 days before	0.8 mg/kg/dose or 50 mg	HD 1, 3	none	13	Postinflammatory hyperpigmentation, mild atrophic scarring, dry eye disease, trichiasis
6 (21)	18 years	F	SMX/TMP	0%**	1 day before	0.8 mg/kg/dose or 50 mg	HD 1	none	4	(–)*
7 (21)	7 years	F	amoxicillin-clavulanate or mefenamic acid	10%	1 day before	0.8 mg/kg/dose or 50 mg	HD 1, 2	none	10	Postinflammatory hyperpigmentation, mild atrophic scarring, trichiasis, excessive tearing
8 (22)	13 years	M	SMX/TMP	(–)*	2 days before	50 mg	HD 2, 5	IV methylprednisolone 5 mg/kg on HD#2, 2.5 mg/kg q8h for 5 days IVIG 1 g/kg/day for 4 days	13	No sequelae
9 (23)	11 years	M	Unidentified	(–)*	(–)*	25mg	HD 1	Prednisone, IVIG	12	(–)*

BSA, body surface area; HD, hospital day; IVIG, intravenous immunoglobulin; SMP/TMP, sulfamethoxazole-trimethoprim.

^*Not mentioned. ^**0% of denudation but 30% of targetoid rash.